IMMB Begins Regulatory Process With US Food & Drug Administration! Details Inside

PennyStockCrowd Newsletter

Immunotech Laboratories (IMMB) – $0.07 Hello Subscribers,Breaking News: IMMB 04/26/2013 – IMMB today announced the company has initiated the Pre-IND and IND process with the US Food & Drug Administration (FDA). The successful submission of an Investigational New Drug (IND) to FDA will permit Immunotech to conduct clinical trials designed to result in marketing approval for a new drug. Read More… [ http://clicks.aweber.com/y/ct/l=DFs9Q&m=3dCK8W0N_fWJIAj&b=QuJkcVkyRV_xm8HfuioAbg ] Begin your research here: http://clicks.aweber.com/y/ct/l=DFs9Q&m=3dCK8W0N_fWJIAj&b=qEYwlCKJ3ZTQHOuQ3KtUmA PSC Video: http://clicks.aweber.com/y/ct/l=DFs9Q&m=3dCK8W0N_fWJIAj&b=swQEyhbtc2xncnXuusIVuA IMMB is a drug development company committed to the commercialization of its proprietary proteins for the treatment of debilitating infectious diseases. Immunotech is committed to creating drugs for the better health of mankind.

IMMB actually helps people. Their HIV treatment can save millions of lives as well as prevent prolonged suffering associated with HIV patients.

IMMB recently announced the company has begun discussions with a professional medical consulting group to start the process for Pre-IND (Investigational New Drug) application in the USA.

This application could pave the way for Immunotech`s patented “IPF” Treatment to be submitted to the Food & Drug Administration (FDA) for approval.

On March 7th, 2013 IMMB entered negotiations with a Canadian Wellness Organization for the use of Immunotech`s Patented AIDS-HIV Treatment.The SAP (special access program) authorizes a manufacturer to sell a drug that cannot otherwise be sold or distributed in Canada.

Drugs considered for release by the SAP include pharmaceutical, biologic, and radiopharmaceutical products and upon satisfactory due diligence and agreement of terms by both parties an agreement such as this could be expedited to implement the legal treatment of the IPF-ITV-1. Treatment, which could result in helping save lives of terminal patients right away. The results from these patients could assist with the Clinical Trials for FDA approval in the United States.

IMMB`s flagship compound ITV-1 (Immune Therapeutic Vaccine-1) is a suspension of Inactivated Pepsin Fraction (IPF), which studies have shown is effective in the treatment of HIV/AIDS. IPF is the active drug substance of ITV-1 and is a purified extract of porcine pepsin. ITV-1 has been shown to modulate the immune system.

How treatment works is: IMMB offers this innovative HIV / AIDS drug, Irreversible Pepsin Fraction (IPF) a platform technology that can be used to facilitate a broad range of applications.

It is free from neurological, gastrointestinal and hematological side effects seen in the anti-retrovirals in use today. Read more… [ http://clicks.aweber.com/y/ct/l=DFs9Q&m=3dCK8W0N_fWJIAj&b=k3uDKQdigu5dTXZEIm_AJA ]Treatments for HIV patients are low cost: less than 500 per treatment and only 3 treatments necessary. Thats remarkable! considering that the cost is less than most peoples medical insurance deductibles these days.

There are approx. 30 million people in Africa alone who suffer from HIV/AIDS.

Follow the CROWD and quickly put IMMB on your RADAR! With such a low market cap and in light of recent developments, IMMB could be one of the most highly undervalued Medical Science plays on the small cap market! Sincerely, PennyStockCrowd.com [ http://clicks.aweber.com/y/ct/l=DFs9Q&m=3dCK8W0N_fWJIAj&b=uop7lJAGro9zJNcjLtLy5g ] Team Discloser, Disclaimers: http://clicks.aweber.com/y/ct/l=DFs9Q&m=3dCK8W0N_fWJIAj&b=zivwNnAb1TnKBUAAMQ_5Ig [ http://clicks.aweber.com/y/ct/l=DFs9Q&m=3dCK8W0N_fWJIAj&b=_SUfrWWMl_._W305MhyZWw ] GENERAL NOTICE AND DISCLAIMER – PLEASE READ CAREFULLY We are engaged in the business of marketing and advertising companies for monetary compensation. All content in our releases is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities.

Neither the information presented nor any statement or expression of opinion, or any other matter herein, directly or indirectly constitutes a solicitation of the purchase or sale of any securities. PennyStockCrowd sponsored advertisements do not purport to provide an analysis of any company`s financial position, operations or prospects and this is not to be construed as a recommendation by PennyStockCrowd or an offer or solicitation to buy or sell any security. Neither the owner of PennyStockCrowd nor any of its members, officers, directors, contractors or employees is licensed broker-dealers, account representatives, market makers, investment bankers, investment advisors, analyst or underwriters .

Investing in securities, including the securities of those companies profiled or discussed on this website is for individuals tolerant of high risks. Viewers should always consult with a licensed securities professional before purchasing or selling any securities of companies profiled or discussed in our releases. It is possible that a viewer`s entire investment may be lost or impaired due to the speculative nature of the companies profiled.

Remember, never invest in any security of a company profiled or discussed in a release or on our website unless you can afford to lose your entire investment. Also, investing in micro-cap securities is highly speculative and carries an extremely high degree of risk. To review our complete disclaimer and additional information, please visit PennyStockCrowd.com.

PennyStockCrowd makes no recommendation that the securities of the companies profiled or discussed in our releases or on our website should be purchased, sold or held by investors.

PLEASE NOTE: This is a paid advertisement but not a solicitation or recommendation to buy or sell securities. PSC has been compensated $5,000 from an unrelated third party (PS LLC) to profile IMMB. PSC does not own shares of IMMB. Please read our full disclosure and disclaimer. Any compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. When compensated by a third party, please be fully aware that the third party may have shares and may liquidate it, which may negatively affect the market.

When PennyStockCrowd.com receives free trading shares as compensation for a profiled company, PSC has previously been compensated 5,000 from PS LLC to profile IMMB.

PennyStockCrowd.com may sell part or all of any such shares during the period in which PennyStockCrowd.com is performing such services. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled companies. In addition, there may be members on this board that receive compensation for particular stock awareness without telling members, so please always use your own buy and sell signals based on your own decisions. Any recent increase in volume or increase in stock price may be due to PennyStockCrowd.com representatives buying.

PennyStockCrowd.com intends to sell shares received as compensation for providing Company Background Information, sending opt-in emails, posting charts, videos, site moderation, consulting etc. We do not give price targets in any of our written or recorded material. PennyStockCrowd.com will not advise as to when we decide to sell and will not offer any opinion as to when others should sell; each investor must make that decision based on his or her judgment of the market. Please do your own research and make your own investment decisions. Always remember that PennyStockCrowd.com is not an analyst and we do not employ or contract any analysts. Investing in securities such as the ones mentioned on our website, in email, or consulted for are for high-risk tolerant individuals only and not the general public.

All direct and third party compensation received will be disclosed within each individual email in accordance with section 17(b) of the 1 9 3 3 Securities Act. Any compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled companies. PennyStockCrowd.com has not investigated the background of the third party, the hiring company. Anyone viewing our website and advertisement should assume that the hiring party and affiliates of the hiring party own shares of the profiled company of which they plan to liquidate, further understanding that the liquidation of those shares will most likely impact the share price of the profiled company negatively.

In preparing this publication,PennyStockCrowd.com has relied upon information supplied by its customers, and press releases which it believes to be reliable; however, such reliability cannot be guaranteed. Investors should not rely on the information contained in this website. Rather, investors should use the information contained in this website as a starting point for doing additional independent research on the featured companies. The advertisements in this website are believed to be reliable, however, PennyStockCrowd.com and its owners, affiliates, subsidiaries, officers, directors, representatives and agents disclaim any liability as to the completeness or accuracy of the information contained in any advertisement and for any omissions of materials facts from such advertisement. PennyStockCrowd.com is not responsible for any claims made by the companies advertised herein, nor is PennyStockCrowd.com responsible for any other promotional firm, its program or its structure.

Many of the companies communicated in our emails or website are developmental stage companies with little or no operating or trading history. The information contained in our alerts should be viewed as commercial advertisement and is not intended to be investment opinion. The report is not provided to any particular individual with a view toward their investment circumstances. The information contained in our alerts is not an offer to buy or sell securities. We distribute opinions, comments and information free of charge to individuals who wish to receive them. Our advertisements and website have been prepared for informational purposes only and are not intended to be used as a complete source of information on any particular company. An individual should never invest in the securities of any of the companies profiles based solely on information contained in our report. Individuals should assume that all information contained in the alerts about profiled companies is not trust worthy unless verified by their own independent research. Any individual who chooses to invest in any securities should do so with caution. Investing in securities is speculative and carries a high degree of risk; you may lose some of all of the money that is invested. Always research your own investments and consult with aregistered investment advisor or licensed stock broker before investing.

Release of Liability: Through use of this website viewing or using you agree to hold PennyStockCrowd.com, its operators owners and employees harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur. The information contained herein is based on sources, which we believe to be reliable, but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data.

Follow the Crowd Team Penny Stock Crowd 3495 South Federal Hwy, STE E, Boynton Beach FL 33435 To

Related posts:

1. IMMB – Medical Science Play could become the Leader in HIV/AIDS Prevention
2. IMMB could be one of the most Undervalued Medical Science Plays! Read Why.
3. Special Report – **SRBL** Will Commence its Exploration Program On Bear Creek Rare Earth Property
4. MEDT is our New Super Sub Penny Medical Marijuana Play! Details Inside…
5. EXMT on High Alert! up 75Pct on heavy volume! Must Read…